Form 10-Q CHARLES RIVER LABORATORI For: Jun 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
JPMorgan Downgrades Charles River Labs (CRL) to Neutral
August 8, 2024 5:55 AM EDTJPMorgan analyst Tycho W. Peterson downgraded Charles River Labs (NYSE: CRL) from Overweight to Neutral with a price target of $205.00 (from $270.00).
The analyst comments "As we noted yesterday in our first take, CRL reported a 2Q top- and bottom-line beat (with the latter aided by $0.30 worth of lower bonus accrual benefit) but took down guidance substantially due to an unexpectedly weaker demand environment in DSA. While buyside expectations assumed a guide cut to 2H24 on a slower pace of recovery in biotech within DSA, the magnitude... More
